Dr. Ghobadi Discusses the Logistics of CAR T-Cell Therapy

Video

In Partnership With:

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.

Once a patient’s white cells are sent to a treatment center, they typically receive lymphodepleting chemotherapy for 3 days. A couple of days later, the patient is infused with the therapy in a way that is similar to blood transfusions, explains Ghobadi. Then, patients are monitored for any side effects, mainly cytokine release syndrome (CRS) and neurotoxicity. Responses can be expected within the next 1 to 3 months.

The most common adverse events (AEs) are CRS and neurotoxicity. Although these events are almost always reversible, they need to be properly monitored, he adds. If a patient does present with an AE, he/she can be treated with a steroid using interleukin-6 or a receptor-blocking agent, such as tocilizumab (Actemra). With the combination of those agents, most of these adverse events are effectively managed.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD